Vericel Corporation received U.S. Food and Drug Administration approval on March 4 2026 for its new MACI manufacturing facility in Burlington, Massachusetts, clearing a key regulatory hurdle that had limited the company’s ability to scale production of its flagship cartilage‑repair product, MACI.
The Burlington plant, completed in 2024 after a construction phase that began in May 2024, is now fully authorized to manufacture MACI products for commercial use. The approval enables Vericel to meet growing demand from orthopedic surgeons, support the launch of MACI Arthro, and position the company for international expansion, including a planned UK regulatory submission in mid‑2026.
Vericel’s 2025 financial results reflected the impact of this milestone: revenue rose 21% year‑over‑year to $276.3 million, with MACI revenue increasing to $239.5 million. Gross profit margins remained strong at 74‑79%, and the company reported earnings per share of $0.45 versus the consensus estimate of $0.39, a beat of $0.06 or 15%. The company’s operating cash flow improved as the new facility’s capacity began to be utilized.
Management highlighted the significance of the approval. President and CEO Nick Colangelo said, "This FDA approval reflects a major achievement for Vericel and underscores the Company's operational and scientific expertise in complex cell therapy manufacturing." He added, "Bringing our Burlington facility online for commercial MACI production strengthens our supply chain and supports our mission to deliver innovative, high‑quality therapies to patients. We look forward to building on this foundation as we continue to scale our business and create long‑term value for patients and shareholders." Colangelo also noted that MACI Arthro provides a less invasive option for MACI administration, which he believes has the potential to significantly increase penetration into the largest segment of the MACI addressable market and will support sustained top‑tier revenue growth for the Company in the years ahead.
The FDA approval is a critical operational enabler that underpins Vericel’s 2026 revenue guidance of $316 million to $326 million, with MACI revenue projected between $280 million and $286 million. The company’s strong gross margins, low debt‑to‑equity ratio, and high liquidity position it to capitalize on the expanded manufacturing capacity and pursue further product launches and geographic expansion.
The addressable market for MACI exceeds $3 billion, yet Vericel has captured less than 7% of that market. The new facility will allow the company to scale production, reduce per‑unit costs through operational leverage, and accelerate market penetration, thereby strengthening its competitive moat in the regenerative medicine space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.